Lung cancer is the world's most common cancer and kills more people than any other cancer. In 2008, approximately 1.52 million new cases of lung cancer were diagnosed worldwide, with 1.31 million people dying from the disease.(14) In the United States, an estimated 161,840 deaths, accounting for 29 percent of all cancer deaths, occurred in 2008, according to the American Cancer Society (ACS).
Discussions of cancer often stress the genetic mutations that drive disease by altering the normal function of cellular proteins.
Genomic studies of cancer patients have revealed thousands of mutations linked to tumor development.
Despite the astounding advances made in understanding the biologic underpinnings of cancer, many cancers are missing obvious genetic drivers.
Lung cancer patients who may not react well to immunotherapy (ICB) could be identified by the oncogenic activation of MYC, an important gene in the development of cancer.
A potential immunotherapy method for treating metastatic melanoma is adoptive cell therapy (ACT). The method, which utilizes the use of immune cells extracted from the patient’s own tumors, could offer cancer patients new options for treatment by eschewing radiation therapies and harsh chemotherapy drugs.
A research team co-led by chemists from City University of Hong Kong recently discovered novel, highly effective anticancer agents with tridimensional structures, which have high anticancer activity, low toxicity and the ability to overcome drug resistance in cancer cells.
Proteomics is the study and analysis of proteins in a biological system, including their structures, functions, associations, and alterations.
Cancer that has spread to areas like the lungs can apply the brakes to a natural pathway that should recruit killer T cells directly to where it has metastasized, scientists report.
Fibroblasts build and maintain the extracellular matrix, or physical scaffolding for cells, in the connective tissues within the body.
Most immunotherapies that aim to increase T cell activity are ineffective in treating estrogen receptor-positive (ER+) breast cancer. A new study of invasive ER+ breast cancers led by researchers at the University of Pittsburgh School of Medicine implies that targeting a different type of immune cell called macrophages may be a more effective approach.
Most immunotherapies, which aim to boost T cell activity, work poorly in treating estrogen receptor-positive (ER+) breast cancer.
In a Phase II trial led by researchers from The University of Texas MD Anderson Cancer Center, adding ipilimumab to a neoadjuvant, or pre-surgical, combination of nivolumab plus platinum-based chemotherapy, resulted in a major pathologic response (MPR) in half of all treated patients with early-stage, resectable non-small cell lung cancer (NSCLC).
Researchers at the Perelman School of Medicine at the University of Pennsylvania have been working on a preclinical study that focuses on a new strategy that uses a “one-two punch” to assist T cells in attacking solid tumors.
Scientists have long known that mitochondria, the "powerhouses" of cells, play a crucial role in the metabolism and energy production of cancer cells.
The Joint Electron Microscopy Center at ALBA (JEMCA) was established through the collaboration of various research agencies to open a new center within the ALBA Synchrotron building that provides electron microscope assistance to the scientific community.
Strata Oncology, Inc., a next-generation precision oncology company enabling smarter and earlier cancer treatment, today announced the publication of a new peer-reviewed study validating the clinical utility of the company's proprietary pan-solid tumor predictive biomarker for anti-PD-1/PD-L1 checkpoint inhibitor monotherapy benefit, Immunotherapy Response Score (IRS).
Immunotherapy -; drug treatment that stimulates the immune system to attack tumors -; works well against some types of cancer, but it has shown mixed success against lung cancer.
The January 2023 issue of SLAS Discovery contains a collection of four full-length articles and one technical brief covering cancer research, high-throughput screening (HTS) assay development and other drug discovery exploration.
Afamitresgene autoleucel (afami-cel; formerly ADP-A2M4), an adoptive T cell receptor (TCR) therapy targeting the MAGE-A4 cancer antigen, achieved clinically significant results for patients with multiple solid tumor types in a Phase I clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.
Cancer experts have tried, sometimes unsuccessfully, to use the total number of mutations in a tumor, called the tumor mutation burden (TMB), to predict a patient's response to immunotherapy.